# Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence

> **NCT06078969** · PHASE2 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 118 (estimated)

## Conditions studied

- Langerhans Cell Histiocytosis of Bone

## Interventions

- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT06078969
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-04
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2024-02-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06078969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06078969, "Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06078969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*